Article

The Potential Clinical and Economic Impact of the Next-Generation COVID-19 mRNA-1283 Vaccine in Canada

2025-05-29

Abstract excerpt

<h4>Background</h4> With continued high disease burden observed in vulnerable groups and fiscal responsibility shifting to Canada’s jurisdictions, assessing the economic value of COVID-19 vaccines is critical for optimizing COVID-19 prevention. This study estimated the public health impact and economically justifiable price (EJP) of Moderna’s next-generation COVID-19 vaccine (mRNA-1283) versus no vaccination in Ca...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 50cc8f1f-4f75-59b6-b1c0-68e5d1fe6c7e
DOI: 10.1101/2025.05.29.25328577

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

The Potential Clinical and Economic Impact of the Next-Generation COVID-19 mRNA-1283 Vaccine in CanadaDOI 10.1101/2025.05.29.25328577Read

Modeling the Cost-Effectiveness of the Next-Generation COVID-19 mRNA-1283 vaccine in the United StatesSemantic proximity Read

Modeling the Anticipated Public Health Benefits of the Next-Generation COVID-19 mRNA-1283 vaccine: An Interim U.S. Population-Level Impact AssessmentSemantic proximity Read

Clinical and Economic impact of updated Fall 2023 COVID-19 vaccines in the Immunocompromised Population in CanadaSemantic proximity Read

Substantial reduction in the clinical and economic burden of disease following variant-adapted mRNA COVID-19 vaccines in immunocompromised patients in FranceSemantic proximity Read

The Potential Clinical and Economic Impact of a Combination COVID-19 and Influenza Vaccine (mRNA-1083) in CanadaSemantic proximity Read

Effectiveness of the 2023–2024 Omicron XBB.1.5-containing mRNA COVID-19 Vaccine (mRNA-1273.815) in Preventing COVID-19–related Hospitalizations and Medical Encounters Among Adults in the United StatesSemantic proximity Read

Comparative effectiveness of mRNA-1273 versus protein-based NVX-CoV2705 vaccination on COVID-19-related outcomes among US insured adults during 2024–2025: a retrospective matched cohort studySemantic proximity Read

Real-World Effectiveness of the mRNA-1273 Vaccine Against COVID-19: Interim Results from a Prospective Observational Cohort StudySemantic proximity Read

Effectiveness of the 2023-2024 Omicron XBB.1.5-containing mRNA COVID-19 vaccine (mRNA-1273.815) in preventing COVID-19-related hospitalizations and medical encounters among adults in the United States: An interim analysisSemantic proximity Read

The potential clinical impact and cost-effectiveness of the updated COVID-19 mRNA Fall 2023 vaccines in the United StatesSemantic proximity Read

Cost-utility analysis of COVID-19 vaccination strategies for endemic SARS-CoV-2 circulation in CanadaSemantic proximity Read

Clinical and Economic Impact of Differential COVID-19 Vaccine Effectiveness in the United StatesSemantic proximity Read